Status | Study |
Recruiting |
Study Name: Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. Condition: Pulmonary Alveolar Proteinosis Date: 2013-11-07 Interventions: Drug: rhGM-CSF GM-CSF will be |
Recruiting |
Study Name: Natural History Study of GATA2 Deficiency and Related Disorders Condition: Myelodysplasia Monocytopenia B Cell Lymphopenia Date: 2013-07-18 |
Recruiting |
Study Name: Rituximab for Anti-cytokine Autoantibody-Associated Diseases Condition: Anticytokine Autoantibody-Associated Diseases Disseminated Non-Tuberculous Mycobacteria Date: 2013-04-25 Interventions: Drug: Rituximab/Rituxan Rituximab is a genetically engineered chimeric murine/human monoclonal antibody |
Completed |
Study Name: Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) Condition: Hereditary Pulmonary Alveolar Proteinosis Date: 2011-12-12 Interventions: Drug: Leukine Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg |
Terminated |
Study Name: Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP) Condition: Pulmonary Alveolar Proteinosis Date: 2009-05-11 Interventions: Drug: GM-CSF [Leukine (Sargramostim)] |
Recruiting |
Study Name: Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Condition: Pulmonary Alveolar Proteinosis Primary Disease Date: 2007-10-31 Interventions: Drug: rituximab IV, 1000 mg, two weeks, 2 times Othe |
Terminated |
Study Name: GM-CSF in Patients With Pulmonary Alveolar Proteinosis Condition: Pulmonary Alveolar Proteinosis Date: 2002-01-30 Interventions: Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) |
Recruiting |
Study Name: Epidemiology of Surfactant Protein-B Deficiency Condition: Lung Diseases Respiratory Distress Syndrome, Newborn Pulmo Date: 2001-04-11 |